GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » EV-to-FCF

CNBX (CNBX Pharmaceuticals) EV-to-FCF : -6.32 (As of Dec. 13, 2024)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CNBX Pharmaceuticals's Enterprise Value is $1.55 Mil. CNBX Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Aug. 2024 was $-0.25 Mil. Therefore, CNBX Pharmaceuticals's EV-to-FCF for today is -6.32.

The historical rank and industry rank for CNBX Pharmaceuticals's EV-to-FCF or its related term are showing as below:

CNBX' s EV-to-FCF Range Over the Past 10 Years
Min: -1875.24   Med: -11.17   Max: -1.12
Current: -6.32

During the past 13 years, the highest EV-to-FCF of CNBX Pharmaceuticals was -1.12. The lowest was -1875.24. And the median was -11.17.

CNBX's EV-to-FCF is ranked worse than
100% of 387 companies
in the Biotechnology industry
Industry Median: 8.7 vs CNBX: -6.32

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-13), CNBX Pharmaceuticals's stock price is $0.009. CNBX Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Aug. 2024 was $-0.015. Therefore, CNBX Pharmaceuticals's PE Ratio (TTM) for today is At Loss.


CNBX Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for CNBX Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals EV-to-FCF Chart

CNBX Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.78 -9.93 -3.52 -14.13 -5.97

CNBX Pharmaceuticals Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.13 -17.46 -8.36 -8.53 -5.97

Competitive Comparison of CNBX Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, CNBX Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNBX Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's EV-to-FCF falls into.



CNBX Pharmaceuticals EV-to-FCF Calculation

CNBX Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1.549/-0.245
=-6.32

CNBX Pharmaceuticals's current Enterprise Value is $1.55 Mil.
CNBX Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CNBX Pharmaceuticals  (OTCPK:CNBX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

CNBX Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.009/-0.015
=At Loss

CNBX Pharmaceuticals's share price for today is $0.009.
CNBX Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.015.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


CNBX Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CNBX Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary